CFI-400945 not checked
Treadwell Therapeutics, Inc · 945 · 400945
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.”In the company’s words, NCT04730258 on ClinicalTrials.gov
- Tested for
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
- Main trialPhase 1/2
- “The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.”In the company’s words, NCT04730258 on ClinicalTrials.gov
- Other names
- 945 · 400945
Other drugs for Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Jan 2026 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026